Queen's School of Business Presentation
Issue link: http://invivo.uberflip.com/i/1501332
Dialogues in Cytomegalovirus 11 A Case-Based Approach to CMV Management Financial Disclosures Dr. Zain Chagla has received an honorarium from Takeda Canada for this article. Correspondence Dr. Zain Chagla Email: chaglaz@mcmaster.ca References 1. Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transplant Infectious Disease. 1999 Jan 1;1:8-12. 2. Azevedo LS, Pierrotti LC, Abdala E, Costa SF, Strabelli TM, Campos SV, Ramos JF, Latif AZ, Litvinov N, Maluf NZ, Pannuti CS. Cytomegalovirus infection in transplant recipients. Clinics. 2015;70:515-23. 3. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar A, The Transplantation Society International CMV Consensus Group. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018 Jun 1;102(6):900-31. 4. Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE, Lischka P. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clinical Infectious Diseases. 2019 Apr 8;68(8):1420-6. 5. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Reviews in Medical Virology. 2008 Jul;18(4):233-46. 6. Gilbert C, Azzi A, Goyette N, Lin SX, Boivin G. Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet. Antimicrobial Agents and Chemotherapy. 2011 Sep;55(9):4019-27. 7. West P, Schmiedeskamp M, Neeley H, Oberholzer J, Benedetti E, Kaplan B. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. Transplant Infectious Disease. 2008 Apr;10(2):129-32. 8. Avery RK, Arav-Boger R, Marr KA, Kraus E, Shoham S, Lees L, Trollinger B, Shah P, Ambinder R, Neofytos D, Ostrander D. Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection. Transplantation. 2016 Oct;100(10):e74 9. Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, Duarte RF, Florescu DF, Kamar N, Kumar D, Maertens J. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clinical Infectious Diseases. 2022 Aug 15;75(4):690-701. 10. Mehta Steinke SA, Alfares M, Valsamakis A, Shoham S, Arav-Boger R, Lees L, Ostrander D, Forman MS, Shedeck A, Ambinder RF, Jones RJ. Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection. Transplant Infectious Disease. 2021 Jun;23(3):e13521. 11. Wey E, Kibbler C. Infections associated with neutropenia and transplantation. Antibiotic and Chemotherapy. 2010:502. 12. Veceric-Haler Z, Kovac D, Tomažic J, Lindic J. Cytomegalovirus Infection Associated Neutropenia and Acute Kidney Gra› Rejection. Journal of Nephrology & Therapeutics. 2017 Jan;7(3):1000293. 13. Belga S, Hernandez C, Kabbani D, Cervera C. 2646. Incidence of myelosuppression related to valganciclovir prophylaxis in solid-organ transplant recipients at high risk of CMV disease. Open Forum Infectious Diseases. 2019 Oct;6(Suppl 2): S925-6. 14. Baradaran H, Hashem Zadeh A, Dashti-Khavidaki S, Laki B. Management of drug-induced neutropenia, thrombocytopenia, and anaemia a›er solid organ transplantation: A comprehensive review. Journal of Clinical Pharmacy and Therapeutics. 2022 Oct 17. 15. Peddi VR, Hariharan S, Schroeder TJ, First MR. Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allogra› recipients. Clinical Transplantation. 1996 Feb 1;10(1 Pt 1):20-3. 16. Bixby AL, Fitzgerald L, Park JM, Kaul D, Tischer S. Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients. Transplant Infectious Disease. 2021 Oct;23(5):e13713.